Table 1 Main characteristics and results of the studies evaluating lymphatic microvessel density prognostic values
Author, Year, Country | Size | Age (mean/median, range) | Antibody dilution | Follow-up (month) (mean/median, range) | Cutoff of lymphatic microvessel density | Results |
|---|---|---|---|---|---|---|
Abe, 2016, Japan [24] | 91 | 54mean (30–81) | D2–40 (1:100) | 120median (8–179) | mean | DFS (+), OS (+) |
Bono, 2004, UK [17] | 180 | 57median (34–89) | LYVE-1 1 μg/mL | 121.2median | median | DFS (+), OS (−) |
Gu, 2008, China [19] | 61 | 57.59mean (29–90) | podoplanin (1:25) | 48.8mean | median | DFS (+), OS (+) |
Mohammed, 2009, UK [21] | 177 | 57median (32–70) | D2–40 (1:100) | 96median (2–184) | median | DFS (+), OS (+) |
Mylona, 2007, Greece [5] | 109 | 56.89mean (25–86) | D2–40 (1:20) | 96.7mean (5–135) | median | DFS (+), OS (+) |
Nakamura, 2005, Japan [6] | 113 | 51median (24–87) | podoplanin (1:200) | 116median (10–230) | 10/mm2 | DFS (+), OS (+) |
Tsutsui, 2010, Japan [22] | 242 | 58.1mean (23–86) | D2–40 (1:50) | 80.64median | 10.67/field | DFS (+), OS (−) |
van der Schaft, 2007, Netherlands [18] | 121 | 61.4mean | Podoplanin (not given) | 80.5mean | median | DFS (+), OS (−) |
Zhang, 2008, China [20] | 70 | 49median (30–77) | D2–40 (1:100) | 68median (28–83) | median | DFS (+), OS (+) |
Zhao, 2012, China [23] | 73 | 53.8mean (29–75) | D2–40 (1:25) | 55mean (8–73) | median | DFS (+), OS (+) |